Add BrightSurf on Google Email

Liquid biopsy-based multi-cancer early detection: an exploration road from evidence to implementation

Liquid biopsy-based multi-cancer early detection (MCED) offers broad population and cancer-type coverage, minimal invasiveness, and high patient compliance. However, significant challenges persist, including balancing surrogate endpoints with public health benefits, detecting early-stage cancers, and minimizing false positives.

SourceScience China Press·JournalScience Bulletin·DateJul 9, 2025

Cancer screenings continue years after guidelines change to limit unnecessary tests, study finds

Researchers found that it took 13 years for cervical cancer screenings to halve among women over 65, and even longer for prostate cancer screenings to decrease significantly. The study emphasizes the need for more effective tracking mechanisms to identify and reduce inappropriate screening practices.

SourceUniversity of Florida·JournalBMJ Quality & Safety·TypeData/statistical analysis·DateJun 9, 2025

The Lancet: Additional imaging techniques detect early stage cancers missed by mammograms in women with dense breasts, finds trial

A randomized controlled trial found that additional imaging techniques such as fast MRI and contrast mammography can detect early-stage cancers in women with dense breasts that were missed by mammograms. The study showed a cancer detection rate of 1.7% for fast MRI and 1.9% for contrast mammography, compared to 0.4% for ultrasound.

SourceThe Lancet·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateMay 21, 2025

New blood test developed at Mass General Brigham shows superior sensitivity in detecting HPV-associated head and neck cancers

A new liquid biopsy blood test called HPV-DeepSeek achieved 99% sensitivity and specificity for diagnosing cancer in asymptomatic patients. The test detected fragments of the viral genome and other features in the blood, outperforming current methods in detecting HPV-associated head and neck cancers.

SourceMass General Brigham·JournalClinical Cancer Research·TypeExperimental study·DateMay 20, 2025

Despite higher sensitivity, multitarget stool DNA tests not as cost-effective for early detection of CRC compared with FIT

Research finds that multitarget stool DNA tests have higher sensitivity than FIT, but are not as cost-effective for early detection of colorectal cancer. Costs per detected advanced neoplasia case or early-detected CRC case are 7- to 9-fold higher for MSDT-based and N-G MSDT-based screening.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeNews article·DateMay 12, 2025

Dr. Adithya Hari joins Pennington Biomedical as physician/nuclear oncologist, adds to center’s strategic expansion of cancer metabolism program

Pennington Biomedical welcomes Dr. Adithya Hari, MD, with expertise in nuclear oncology and translational science, strengthening cancer research and patient-centered innovation in Louisiana. He will establish a research program focused on nuclear medicine and dedicate time to direct patient care through a clinical partnership.

Non-risk-based lung cancer screening with low-dose computed tomography

A non-risk-based lung cancer screening approach using low-dose computed tomography (LDCT) in Chinese populations detects a significant number of early-stage lung cancers. The study found that incorporating non-high-risk individuals into screening programs can lead to a greater detection rate and improved patient outcomes.

SourceNational Center for Respiratory Medicine·JournalJAMA·TypeRandomized controlled/clinical trial·DateApr 29, 2025

Do disasters delay early cancer diagnoses?

A recent analysis found that rates of colorectal cancer diagnoses dropped during Hurricanes Irma and Maria and the COVID-19 pandemic in Puerto Rico, but late-stage diagnoses eventually exceeded expectations. Limited access to cancer screening services due to these disasters likely hindered timely CRC diagnoses.

SourceWiley·JournalCancer·DateApr 14, 2025

Study finds rates of breast and colorectal cancer screening nearly four-fold higher than lung cancer screening among those eligible

A new study by Mass General Brigham researchers reveals that many eligible patients who receive other preventative screenings are not getting screened for lung cancer. The study found that 65% of those eligible received breast and colorectal cancer screening, a nearly 4-fold higher rate than lung cancer screening.

SourceMass General Brigham·JournalJAMA·TypeData/statistical analysis·DateApr 2, 2025

Patient navigators improve colonoscopy rates after abnormal stool tests, study shows

A study found that patient navigators significantly improved one-year follow-up colonoscopy completion rates by 12% and reduced time to follow-up by 27 days. The researchers emphasize the importance of timely follow-up colonoscopies for patients with abnormal stool test results.

SourceUniversity of Arizona Health Sciences·JournalAnnals of Internal Medicine·TypeRandomized controlled/clinical trial·DateMar 31, 2025

Three out of ten breast cancers are detected between screenings

A new study found that interval cancers, which are detected between two screening sessions, account for 30% of all breast cancers. Women with high breast density, hormone therapy, and a family history of breast cancer are at increased risk. More frequent or improved screening methods could significantly improve early detection rates.

SourceKarolinska Institutet·JournalJAMA Oncology·TypeObservational study·DateMar 27, 2025

Study: new guidelines expanded access to lung cancer screening, but gaps remain in reaching rural and uninsured populations

The updated guidelines substantially increased lung cancer screenings overall, but disparities persist among people with limited access to healthcare. Barriers include cost, knowledge, and lack of primary care providers, with mobile units and patient navigators offering potential solutions.

UTEP Researchers develop portable, blood-based device that detects colon cancer

Researchers at the University of Texas at El Paso have developed a portable, blood-based device that can detect colon cancer using a biomarker called CCSP-2. The device has the potential to provide early detection and treatment options for this second-deadliest US cancer, making it a significant advancement in colorectal cancer screening.

SourceUniversity of Texas at El Paso·JournalACS Measurement Science Au·DateMar 13, 2025

Long visit in the ER? It’s a good time to learn about cervical cancer screening

Researchers found that women who received text message reminders were twice as likely to get their cervical cancer screenings within 150 days compared to those without reminders. The study suggests a promising low-cost approach to increasing cancer screenings in underserved populations.

SourceUniversity of Rochester Medical Center·JournalAcademic Emergency Medicine·TypeRandomized controlled/clinical trial·DateMar 11, 2025

People with intellectual disabilities less likely to participate in population screening

Research from Radboud University Medical Center found that people with intellectual disabilities are significantly less likely to participate in cancer screenings for cervical, breast, and colon cancer. The results highlight the need for better alignment of screening programs with the needs of individuals with intellectual disabilities.

SourceRadboud University Medical Center·JournalThe Lancet Public Health·TypeSurvey·DateMar 4, 2025

Influencers promoting ‘overwhelmingly’ misleading information about medical tests on social media

A global study found that social media influencers promote controversial medical tests with limited scientific evidence, often without mentioning potential harms. The tests include full-body MRI scans, genetic testing, blood tests, and gut microbiome tests. Experts warn that these tests can lead to overdiagnosis and overuse.

SourceUniversity of Sydney·JournalJAMA Network Open·DateFeb 26, 2025